Patents by Inventor Jean-Francois Haeuw
Jean-Francois Haeuw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11673931Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.Type: GrantFiled: April 1, 2020Date of Patent: June 13, 2023Assignee: PIERRE FABRE MEDICAMENTInventors: Peter Lowe, Jean-François Haeuw, Alicia Contet, Céline Bertaux, Barbara Akla, Marie-Claire Janin-Bussat, Martine Malissard, Juliette Trepreau
-
Patent number: 11661457Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: GrantFiled: February 26, 2020Date of Patent: May 30, 2023Assignee: PIERRE FABRE MEDICAMENTInventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
-
Publication number: 20220105195Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: November 15, 2021Publication date: April 7, 2022Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-François HAEUW, Marie LAMOTHE
-
Publication number: 20220048966Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.Type: ApplicationFiled: September 30, 2019Publication date: February 17, 2022Applicant: PIERRE FABRE MEDICAMENTInventors: Peter LOWE, Jean-François HAEUW, Alicia CONTET, Céline BERTAUX, Barbara AKLA, Marie-Claire JANIN-BUSSAT
-
Publication number: 20220023438Abstract: The present invention relates to a linker of the following formula (I) or a salt thereof: (I). The present invention relates to a linker-drug conjugate of the following formula (II) or a salt thereof: (II). The present invention relates also to a binding unit-drug corrugate, such as an antibody-drug conjugate, of the following formula (III) or (IV) or a salt thereof: (III), (IV), as well as a pharmaceutical composition comprising such a binding unit-drug corrugate and its use in the treatment of cancer.Type: ApplicationFiled: September 27, 2019Publication date: January 27, 2022Applicant: PIERRE FABRE MEDICAMENTInventors: Michel PEREZ, Frédéric MARION, Jean-François HAEUW, Cyrille DREYFUS
-
Patent number: 11219693Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drag selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drag-conjugate for the treatment of cancer.Type: GrantFiled: April 16, 2019Date of Patent: January 11, 2022Assignee: PIERRE FABRE MEDICAMENTInventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-François Haeuw, Marie Lamothe
-
Publication number: 20210038738Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: October 28, 2020Publication date: February 11, 2021Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Marie Lamothe
-
Patent number: 10858423Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.Type: GrantFiled: October 26, 2016Date of Patent: December 8, 2020Assignee: PIERRE FABRE MEDICAMENTInventors: Alexandra Jouhanneaud, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert, Jean-François Haeuw, Ian Rilatt, Michel Perez, Marie Lamothe
-
Publication number: 20200308242Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.Type: ApplicationFiled: April 1, 2020Publication date: October 1, 2020Applicant: PIERRE FABRE MEDICAMENTInventors: Peter LOWE, Jean-François HAEUW, Alicia CONTET, Céline BERTAUX, Barbara AKLA, Marie-Claire JANIN-BUSSAT
-
Publication number: 20200270352Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: February 26, 2020Publication date: August 27, 2020Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT, Marie LAMOTHE
-
Patent number: 10633448Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: GrantFiled: April 27, 2015Date of Patent: April 28, 2020Assignee: PIERRE FABRE MEDICAMENTInventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
-
Publication number: 20190269788Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: April 16, 2019Publication date: September 5, 2019Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-François HAEUW, Marie LAMOTHE
-
Publication number: 20190202901Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.Type: ApplicationFiled: October 26, 2016Publication date: July 4, 2019Inventors: Alexandra JOUHANNEAUD, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Thierry CHAMPION, Robert ALAIN, Jean-François HAEUW, Ian RILATT, Michel PEREZ
-
Patent number: 10314921Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: GrantFiled: April 27, 2015Date of Patent: June 11, 2019Assignee: PIERRE FABRE MEDICAMENTInventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Marie Lamothe
-
Publication number: 20180228915Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: January 31, 2018Publication date: August 16, 2018Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW
-
Publication number: 20170043032Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: April 27, 2015Publication date: February 16, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW
-
Publication number: 20170043031Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: April 27, 2015Publication date: February 16, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Mathieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT
-
Patent number: 8808999Abstract: The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.Type: GrantFiled: January 18, 2012Date of Patent: August 19, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Publication number: 20140193329Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: ApplicationFiled: October 9, 2013Publication date: July 10, 2014Applicant: Pierre Fabre MedicamentInventor: Jean-François HAEUW
-
Patent number: 8697855Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanized, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: GrantFiled: April 5, 2012Date of Patent: April 15, 2014Assignee: Pierre Fabre MedicamentInventor: Jean-François Haeuw